Chesapeake Financial Shares Inc. (CPKF) Launches Bank-Owned SMB Payments Utility With Rebolt

Chesapeake Financial Shares, Inc. (parent of Chesapeake Bank and Chesapeake Wealth Management) reported Q2 2026 net income of $8.18M and fully diluted EPS of $1.745, including a $2.7M one-time gain from selling its Bearing Insurance stake. Total assets were $1.73B, up 5.8% YoY. The board declared a $0.18 quarterly dividend effective Sept. 1, 2026.

ByteDance, Alibaba, and Tencent ordered over 3 million Nvidia RTX PRO 5500 graphics cards, valued at over $35 billion, according to Reuters. Nvidia warned of potential delivery shortages due to high demand. The chips are for AI inference and comply with U.S. export controls. Nvidia expects to deliver the first samples in December 2026, with commercial shipments starting in Q1 2027.

Revolution Medicines (RVMD) has started a Phase 3 trial for its lung cancer treatment, zoldonrasib, in combination with standard care. The trial aims to evaluate the treatment's efficacy in patients with non-squamous non-small cell lung cancer with the RAS G12D mutation. Primary endpoint is progression-free survival, with secondary endpoints including overall survival and safety. RVMD shares were up 6.90% at $194.71 at the time of publication.

Apple is expanding its U.S. Manufacturing Program, committing up to $100 million over three years to Perryman Co. for titanium supplies and expanding its partnership with Qnity Electronics for iPhone 18 Pro camera components. The move supports U.S. jobs and domestic supply chains for the iPhone Duo and iPhone 18 Pro, according to the company.

AWS launched TorchNeuron, enabling PyTorch apps to run on Trainium with minimal changes, challenging Nvidia's dominance. AWS claims 85% of AI apps use PyTorch, where Nvidia's CUDA is embedded. Nvidia released Nemotron 3.5 models, including a 120B-parameter model for enterprise agents, claiming performance advantages over competitors. Both companies are expanding their AI offerings, targeting startups and enterprises.

Teva (TEVA) and Sanofi (SNY) reported positive Phase 2b data for duvakitug, showing sustained benefits in ulcerative colitis and Crohn's disease through Week 44. Clinical remission rates varied by dose, with higher rates observed at 900 mg. The drug was generally well tolerated. Both companies are advancing duvakitug into Phase 3 studies. SNY is up 4.11% at $41.19, while TEVA is down 0.41% at $41.14.